lovastatin has been researched along with Colorectal Neoplasms in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, JH; Du, JJ; Huang, JJ; Huang, XM; Huang, Z; Lin, QY; Lin, WJ; Long, Z; Ma, WZ; Qin, X; Shen, YF; Yang, Y; Zhang, N; Zheng, BW; Zhong, FF | 1 |
| Diks, S; Fühler, GM; Hardwick, JCH; Hawinkels, LJAC; Heijmans, J; Jacobs, RJ; Kodach, LL; Ouahoud, S; Peppelenbosch, MP; Voorneveld, PW; Wildenberg, ME | 1 |
| Corcos, L; Durand, S; Le Jossic-Corcos, C; Saint-Pierre, A; Trillet, K; Uguen, A | 1 |
| Ghasemi, K; Hashemitabar, M; Mahdavinia, M; Razzazzadeh, S; Rezaei, M; Zeidooni, L | 1 |
| Xiao, H; Yang, CS | 1 |
| Kenna, T; Mattarollo, SR; Nicol, AJ; Nieda, M | 1 |
| Bleuming, SA; Hardwick, JC; Hommes, DW; Kodach, LL; Peppelenbosch, MP; van den Brink, GR | 1 |
| Akoglu, B; Stein, J; Wächtershäuser, A | 1 |
1 review(s) available for lovastatin and Colorectal Neoplasms
| Article | Year |
|---|---|
Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Atorvastatin; Celecoxib; Colorectal Neoplasms; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Evidence-Based Medicine; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Meta-Analysis as Topic; Neoplasms; Pravastatin; Pyrazoles; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Sulfonamides; Sulindac | 2008 |
7 other study(ies) available for lovastatin and Colorectal Neoplasms
| Article | Year |
|---|---|
Autophagy inhibitors increase the susceptibility of KRAS-mutant human colorectal cancer cells to a combined treatment of 2-deoxy-D-glucose and lovastatin.
Topics: Animals; Antimetabolites; Autophagy; Cell Survival; Chloroquine; Colorectal Neoplasms; Deoxyglucose; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HCT116 Cells; HEK293 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Proto-Oncogene Proteins p21(ras); Xenograft Model Antitumor Assays | 2021 |
Kinome-wide analysis of the effect of statins in colorectal cancer.
Topics: Animals; Cell Line, Tumor; Colorectal Neoplasms; Female; HCT116 Cells; HT29 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mice; Mice, Nude; Phosphoproteins; Phosphorylation; Phosphotransferases; Protein Processing, Post-Translational; Proteome; Signal Transduction | 2021 |
A transcriptome-based protein network that identifies new therapeutic targets in colorectal cancer.
Topics: Colorectal Neoplasms; Gene Expression Profiling; HT29 Cells; Humans; Lovastatin; Molecular Targeted Therapy; Protein Interaction Maps | 2017 |
Gamma-tocopherol enhances apoptotic effects of lovastatin in human colorectal carcinoma cell line (HT29).
Topics: Apoptosis; Caspase 3; Colorectal Neoplasms; Cytochromes c; Drug Synergism; gamma-Tocopherol; HEK293 Cells; HT29 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Signal Transduction | 2014 |
Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Burkitt Lymphoma; Carcinoma; Cell Line, Tumor; Cisplatin; Colorectal Neoplasms; Concanavalin A; Cytotoxicity, Immunologic; Diphosphonates; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Genes, T-Cell Receptor delta; Genes, T-Cell Receptor gamma; Humans; Imidazoles; Interferon-gamma; Lovastatin; Lung Neoplasms; Male; Membrane Glycoproteins; Neoplasms; Perforin; Pore Forming Cytotoxic Proteins; Prostatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Urinary Bladder Neoplasms; Vincristine; Zoledronic Acid | 2007 |
The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Carrier Proteins; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Genes, Reporter; HCT116 Cells; HT29 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Luciferases; Mice; Mice, Nude; Signal Transduction; Simvastatin; Smad4 Protein; Transfection; Transforming Growth Factor beta; Up-Regulation; Xenograft Model Antitumor Assays | 2007 |
HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2.
Topics: Butyrates; Caco-2 Cells; Cell Cycle; Cell Division; Colorectal Neoplasms; Drug Synergism; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin | 2001 |